Liver Sinusoidal Endothelial Cells (LSECs) play a crucial role in maintaining liver homeostasis, regulating immune responses, and fibrosis in liver diseases. This review explores the unique functions of LSECs in liver pathology, particularly their roles in immune tolerance, antigen presentation, and the modulation of hepatic stellate cells (HSCs) during fibrosis. LSECs act as key regulators of immune balance in the liver by preventing excessive immune activation while also filtering antigens and interacting with immune cells, including Kupffer cells and T cells. Metabolic Dysfunction-Associated Fatty Liver Disease(MAFLD) is significant because it can lead to advanced liver dysfunction, such as cirrhosis and liver cancer. The prevalence of Metabolic Associated Steatohepatitis (MASH) is increasing globally, particularly in the United States, and is closely linked to rising rates of obesity and type 2 diabetes. Early diagnosis and intervention are vital to prevent severe outcomes, highlighting the importance of studying LSECs in liver disease. However, during chronic liver diseases, LSECs undergo dysfunction, leading to their capillarization, loss of fenestrations, and promotion of pro-fibrotic signaling pathways such as Transforming growth factor-beta (TGF-β), which subsequently activates HSCs and contributes to the progression of liver fibrosis. The review also discusses the dynamic interaction between LSECs, HSCs, and other hepatic cells during the progression of liver diseases, emphasizing how changes in LSEC phenotype contribute to liver scarring and fibrosis. Furthermore, it highlights the potential of LSECs as therapeutic targets for modulating immune responses and preventing fibrosis in liver diseases. By restoring LSECs’ function and targeting pathways associated with their dysfunction, novel therapies could be developed to halt or reverse liver disease progression. The findings of this review reinforce the importance of LSECs in liver pathology and suggest that they hold significant promises as targets for future treatment strategies aimed at addressing chronic liver diseases.
The use of social media platforms in pathology and medical laboratory science has increased in recent years, revolutionizing the way professionals in these fields interact, disseminate information, and collaborate. To gain an understanding of the current landscape regarding social media use in pathology and medical laboratory science, a novel systematic review was conducted. A search of PubMed, Medline, Embase, and Scopus was performed to identify articles evaluating social media use within pathology and medical laboratory science. Articles published in English within the previous 10 years were searched on December 22, 2022. Inclusion criteria were articles containing information regarding social media utility in pathology or laboratory medicine and related articles that mentioned specific hashtags for pathology. The review process involved analyzing the social media platforms referenced, hashtags mentioned, and the presence of international authors as key endpoints of interest. 802 publications were identified; 54 studies met inclusion criteria. Subspecialties represented were considered, but none were found to be statistically significant. X/Twitter (n = 42) was the most discussed social media platform. The top hashtags discussed were #pathJC (5.1%), #dermpathJC (4.2%), #USCAP2016 (3.4%), and #PathBoards (3.4%). Analysis of these articles provides insights into current trends, including the social media platforms referenced, hashtags used, and involvement of international authors. This review will contribute to a deeper understanding of the role and impact of social media in these fields, highlighting opportunities and challenges for future research and practice in pathology and lab medicine.
PURPOSE: Metastatic hormone-sensitive prostate cancer (mHSPC) is a heterogeneous disease state with multiple treatment options. Biomarkers are needed for risk stratification and to guide treatment intensification or deintensification. We used a computational histology artificial intelligence–based platform (CHAI) to develop and validate a digital image–only prognostic biomarker in mHSPC with participant-level data from two prospective, phase III randomized controlled trials. METHODS: The CHAI platform extracted quantitative histomorphologic features from whole-slide images of hematoxylin and eosin–stained diagnostic specimens. Data from CHAARTED were used to construct a signature of features associated with overall survival (OS). A continuous risk score was dichotomized into favorable- and unfavorable-risk groups. The performance of the locked model was assessed in ENZAMET as an independent validation cohort using Kaplan-Meier methods and multivariable Cox proportional hazards models. Institutional review board approval was obtained for each participating data set. Given all patient information was deidentified, the study was considered institutional review board–exempt and consent waived. RESULTS: Overall, 1,191 participants were included: 507 in development (CHAARTED) and 684 in validation (ENZAMET). In the validation cohort, CHAI unfavorable-risk participants had worse OS (hazard ratio [HR], 2.6 [95% CI, 2.0 to 3.4]; P < .001) and progression-free survival (PFS; HR, 2.2 [95% CI, 1.7 to 2.7]; P < .001). Five-year OS was 39% for unfavorable-risk versus 69% for favorable-risk participants. In adjusting for clinical variables, the biomarker remained prognostic for OS and PFS ( P < .001). Among those who received doublet (androgen-deprivation therapy [ADT] plus androgen receptor pathway inhibitor [ARPI]) versus triplet systemic therapy (ADT plus docetaxel plus ARPI), there was a significant interaction between biomarker and treatment intensification for OS ( P = .003) and PFS ( P < .001), suggesting that patients at higher risk may benefit more from triplet therapy. CONCLUSION: We developed and validated an image-only AI-based biomarker associated with clinical outcomes and potential benefit from treatment escalation in mHSPC independent of conventional clinicopathologic risk factors.
1 September 2017 in Archives of Pathology & Laboratory Medicine
ASAdam L. Booth, MD1; Diana Rodgers, MD2; Phillip Osehobo, MD, PhD2; Lalarukh K. Aftab, MD3; Mahmoud A. Eltorky, MD2; Heather L. Stevenson, MD, PhD11Department of Pathology, University of Texas Medical Branch, Galveston2Department of Pathology, WellStar Spa
Adam L. Booth, MD1; Diana Rodgers, MD2; Phillip Osehobo, MD, PhD2; Lalarukh K. Aftab, MD3; Mahmoud A. Eltorky, MD2; Heather L. Stevenson, MD, PhD11Department of Pathology, University of Texas Medical Branch, Galveston2Department of Pathology, WellStar Spa
YSYing Liu, MD, PhD; Lynne Opitz, MD; Guo-Xia Tong, MD, PhDDepartment of Pathology and Laboratory Medicine, Staten Island University Hospital, Sta
Ying Liu, MD, PhD; Lynne Opitz, MD; Guo-Xia Tong, MD, PhDDepartment of Pathology and Laboratory Medicine, Staten Island University Hospital, Sta
+1995
Article Citation: (2017) Abstracts and Case Studies From the College of American Pathologists 2017 Annual Meeting (CAP17). Archives of Pathology & Laboratory Medicine: September 2017, Vol. 141, No. 9, pp. e2-e191. https://doi.org/10.5858/arpa.2017-0238-AB
1
15 May 2026 in Journal of Pathology and Translational Medicine
Digital and computational pathology are expanding rapidly worldwide, driven by advances in whole-slide imaging, AI algorithms, multimodal data integration, and improved digital infrastructure. Adoption continues to accelerate in the United States and internationally, supported by professional guidelines, emerging reimbursement pathways, and the growing need for remote workflows and collaborative diagnostics. Progress in interoperability standards, regulatory frameworks, and FDA approvals has strengthened the foundation for clinical deployment, while large-scale data repositories and federated learning approaches enable more robust and privacy-preserving model development. Foundation models, multimodal AI systems, and LLM-based copilots are reshaping diagnostic support, prognostication, workflow efficiency, clinical trials and drug discovery.